慢性丙型肝炎合并非酒精性脂肪性肝病患者血清RBP4和SREBP-1c水平变化分析*

doi:10.3969/j.issn.1672-5069.2023.02.009

Abstract

Abstract: Objective The aim of this study was to explore the implication of serum retinol-binding protein 4 (RBP4) and sterol regulatory element-binding protein-1c (SREBP-1c) in patients with chronic hepatitis C (CHC) and non-alcoholic fatty liver diseases (NAFLD). Methods A total of 94 patients with CHC were admitted to our hospital between February 2019 and February 2022, and all underwent liver biopsy and were treated with recombinant human interferon-α 2a and ribavirin for 24 weeks. The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated. Serum RBP4 and SREBP-1c levels were detected by ELISA. Results The liver histopathological examination revealed NAFLD in 50 cases (53.2%), including 22 (44.0%) with mild and 28 (56.0%) with moderate-severe (M/S) steatosis in our series; serum AST, ALT, ALP and GGT levels in patients with M/S steatosis were(62.2±12.8)U/L, (87.2±11.5)U/L, (99.0±14.4)U/L and (69.4±10.3)U/L, much higher than [(53.6±10.1)U/L, (75.7±12.5)U/L, (83.8±12.7)U/L and (58.5±7.7)U/L, respectively, P<0.05] in patients with mild steatosis or [(51.7±8.5)U/L,(73.5±13.8)U/L,(81.6±10.9)U/L and (56.2±8.1)U/L, respectively, P<0.05] in patients with CHC; serum RBP4 and SREBP-1c levels in patients with M/S steatosis were (55.9±8.2) mg/L and (40.1±7.4)μg/L, significantly higher than [(36.7±5.8)mg/L and (29.3±5.1)μg/L, respectively, P<0.05] in patients with mild steatosis or [(28.4±6.3)mg/L and (21.8±5.5)μg/L, P<0.05] in patients with CHC; serum HbA1c and HOMA-IR in patients with M/S steatosis were (5.7±0.5)% and (3.2±0.5), both significantly higher than [(5.3±0.5)% and (2.5±0.4), P<0.05] in patients with mild steatosis or [(5.1±0.3)% and (1.9±0.3), P<0.05] in patients with CHC; serum RBP4 and SREBP-1c levels in 41 patients who responded to interferon-α 2a therapy were (25.7±6.0)mg/L and (20.6±5.0)μg/L, much lower than [(48.5±7.4)mg/L and (35.5±6.3)μg/L, P<0.05] in 53 patients who didn’t. Conclusion Serum RBP4 and SREBP-1c levels in patients with CHC and NAFLD increase, which might interferes with antiviral therapy, and warrants further investigation.

Key words: Hepatitis C, Non-alcoholic fatty liver diseases, Interferon-α 2a, Retinol-binding protein 4, Sterol regulatory element-binding protein-1c, Response

Fan Mingfang, Tian Ying, Zhou Qian, et al.. Changes of serum RBP4 and SREBP-1c levels in patients with chronic hepatitis C and non-alcoholic fatty liver diseases[J]. Journal of Practical Hepatology, 2023, 26(2): 185-188.

References

[1] Koch LK, Yeh MM. Nonalcoholic fatty liver disease (NAFLD): diagnosis, pitfalls, and staging. Ann Diagn Pathol, 2018, 37(1): 83-90.
[2] Asselah T, Rubbia-Brandt L, Marcellin P, et al. Steatosis in chronic hepatitis C: why does it really matter? Gut, 2006, 55(1): 123-130.
[3] Cheng FK, Torres DM, Harrison SA. Hepatitis C and lipid metabolism, hepatic steatosis, and NAFLD: still important in the era of direct acting antiviral therapy? J Viral Hepat, 2014, 21(1): 1-8.
[4] 莫超艳, 杨有强, 钟嫄, 等. 非酒精性脂肪性肝病合并2型糖尿病患者血清抵抗素和黄醇结合蛋白4水平及其临床意义探讨. 实用肝脏病杂志, 2022, 25(2): 231-234.
[5] Petta S, Cammà C, Di Marco V, et al. Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis C virus genotype 1. Hepatology, 2008, 48(1): 28-37.
[6] Jackel-Cram C, Qiao L, Xiang Z, et al. Hepatitis C virus genotype-3a core protein enhances sterol regulatory element-binding protein-1 activity through the phosphoinositide 3-kinase-Akt-2 pathway. J Gen Virol, 2010, 91(6): 1388-1395.
[7] 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019年版). 实用肝脏病杂志, 2020, 23(1): 33-52.
[8] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版). 实用肝脏病杂志, 2018, 21(2): 177-186.
[9] Toyoda H, Kumada T, Kiriyama S, et al. Association between hepatic steatosis and hepatic expression of genes involved in innate immunity in patients with chronic hepatitis C. Cytokine, 2013, 63(2): 145-150.
[10] Dyal HK, Aguilar M, Bhuket T, et al. Concurrent obesity, diabetes, and steatosis increase risk of advanced fibrosis among HCV patients: a systematic review. Dig Dis Sci, 2015, 60(9): 2813-2824.
[11] 张晓伟, 钟蕊. 索磷布韦和维帕他韦联合利巴韦林治疗基因2、3型慢性丙型肝炎患者近期疗效和耐受性观察. 实用肝脏病杂志, 2020, 23(2): 191-194.
[12] Kilicarslan M, Weijer BA, Simonyte Sjodin K, et al. RBP4 increases lipolysis in human adipocytes and is associated with increased lipolysis and hepatic insulin resistance in obese women. FASEB J, 2020, 34(5): 6099-6110.
[13] Kloting N, Graham TE, Berndt J, et al. Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell Metabol, 2007, 6(1): 79-87.
[14] Steinhoff JS, Lass A, Schupp M. Retinoid homeostasis and beyond: how retinol binding protein 4 contributes to health and disease. Nutrients, 2022, 14(6): 1236.
[15] 刘滨菘, 李强, 王薇, 等. 视黄醇结合蛋白4与非酒精性脂肪肝病的相关研究. 中华内分泌代谢杂志, 2013, 29(1): 58-61.
[16] Zhang ZH, Ke JF, Lu JX, et al. Serum retinol-binding protein levels are associated with nonalcoholic fatty liver disease in Chinese patients with type 2 diabetes mellitus: a real-world study. Diabetes Metab J, 2022, 46(1): 129-139.
[17] Stefan N, Hennige AM, Staiger H, et al. High circulating retinol-binding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocellular fat in humans. Diabetes Care, 2007, 30(5): 1173-1178.
[18] 杨朝霞, 孙航, 沈薇. 非酒精性脂肪性肝病患者肝脏固醇调节元件结合蛋白-1c的表达及其意义. 中华肝脏病杂志, 2008, 16(11): 823-826.
[19] Nguyen TTP, Kim DY, Lee YG, et al. SREBP-1c impairs ULK1 sulfhydration-mediated autophagic flux to promote hepatic steatosis in high-fat-diet-fed mice. Mol Cell, 2021, 81(18): 3820-3832.
[20] Lucero D, Miksztowicz V, Macri V, et al. Overproduction of altered VLDL in an insulin-resistance rat model: Influence of SREBP-1c and PPAR-α. Clin Investig Arterioscler, 2015, 27(4): 167-174.

Changes of serum RBP4 and SREBP-1c levels in patients with chronic hepatitis C and non-alcoholic fatty liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Fang Ying, Jin Jiadong, Wang Fu, et al.. Impact of COVID-19 pandemic on emotions and liver function tests in patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(2): 193-196.
[2]	Li Xiaomeng, Wu Shaoyu, Wang Yuanyuan. Implication of serum homocystein, fibroblast growth factor-21 and nuclear factor-κB levels in patients with non-alcoholic fatty liver diseases and T2DM [J]. Journal of Practical Hepatology, 2023, 26(2): 202-205.
[3]	Huang Danxia, Zhao Zhihui, Xiao Yuexing, et al. Berberine improves liver injuries and intestinal flora disorders in high-fat diet-induced non-alcoholic fatty liver disease in rats [J]. Journal of Practical Hepatology, 2023, 26(1): 23-26.
[4]	Xu Weiqiang, Liu Shuping, Li Xiaomeng. Risk factors of non-alcoholic fatty liver diseases in physical examination individuals [J]. Journal of Practical Hepatology, 2023, 26(1): 35-38.
[5]	Wu Chengyong, Chen Chong, Liu Wenyan, et al. Prevalence of bacterial infection in patients with HBV-related acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2023, 26(1): 59-62.
[6]	Zhang Fu, Chen Junmao, Liang Xiaohui. Efficacy of primary suture laparoscopic common bile duct exploration in the treatment of patients with choledocholithiasis [J]. Journal of Practical Hepatology, 2023, 26(1): 128-131.
[7]	Wu Fengping, Cui Dandan, Wang Yikai, et al.. Serum B-cell activating factor levels in predicting antiviral response of pegylated interferon alpha in inactive HBsAg carriers [J]. Journal of Practical Hepatology, 2022, 25(6): 780-783.
[8]	Qi Xiaoan, Lu Jinxi, Yuan Lin. Correlation of polymorphisms of calcitonin gene-related peptide and α-interferon-λ4 genes to response to α-interferon therapy in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2022, 25(6): 784-787.
[9]	Xu Hailing, Qin Gang, Xue Hong, et al.. Response to elbavir/glarevir antiviral therapy in patients with genotype 1b chronic hepatitis C [J]. Journal of Practical Hepatology, 2022, 25(6): 788-791.
[10]	Cai Yong, Li Jing, Ou Qin. Implications of serum omentin, retinol-binding protein-4 and propeptide of type I procollagen in patients with diabetes mellitus type 2 and non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(6): 800-803.
[11]	Fan Ye, Zhang Ximei, Zhang Yan. Clinical implication of serum cystatin C, lipoprotein α and nesfatin-1 levels in patients with non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(6): 816-819.
[12]	Zeng Ting, Lei Xiangyang, Bai Xiaosu. Protective effect of oxymatrine on liver steatosis in rats with high-fat-induced non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(5): 624-627.
[13]	Gao Zhiguo, Wang Bingyuan. Hepatic artery buffering response in patients with severe acute alcoholic hepatitis [J]. Journal of Practical Hepatology, 2022, 25(5): 753-756.
[14]	Jia Ting, Li Junyi, Zhang Xiuling, et al. Serologic response toentecavir and pegylated interferon α-2b combination in treatment of patients with low serum level HBsAg-positive chronic hepatitis B [J]. Journal of Practical Hepatology, 2022, 25(4): 488-491.
[15]	Xu Huan, Wang Guangli, Dong Dandan, et al. Efficacy of standardized pegylated interferon α-2a and ribavirin combination in treatment of patients with chronic hepatitis C [J]. Journal of Practical Hepatology, 2022, 25(4): 500-503.